Pharmala Biotech Holdings Inc (MDMA) Stock Price & News

All values in CAD	2025-ж. авг.	2025-ж. ноя.	2026-ж. фев.	2026-ж. май
Revenue	267,38 миң	206,44 миң	280,58 миң	513,23 миң
Cost of goods sold	34,04 миң	34,84 миң	22,41 миң	174,69 миң
Cost of revenue	34,04 миң	34,84 миң	22,41 миң	174,69 миң
Research and development expenses	44,91 миң	41,10 миң	40,53 миң	44,91 миң
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	404,68 миң	320,96 миң	367,29 миң	472,32 миң
Operating expense	553,47 миң	498,41 миң	559,82 миң	810,59 миң
Total operating expenses	587,50 миң	533,25 миң	582,22 миң	985,28 миң
Operating income	-320,13 миң	-326,81 миң	-301,64 миң	-472,05 миң
Other non operating income	-41,00 миң	-16,84 миң	-46,18 миң	-40,97 миң
EBT including unusual items	-361,13 миң	-409,70 миң	-337,70 миң	-499,76 миң
EBT excluding unusual items	-361,13 миң	-343,65 миң	-347,82 миң	-513,01 миң
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-361,13 миң	-409,70 миң	-337,70 миң	-499,76 миң
Net profit margin	-135,07%	-198,46%	-120,35%	-97,37%
Earnings per share	-	-	-	-
Interest and investment income	-	-	-	-
Interest expense	-	-	-	-
Net interest expenses	-	-	-	-
Depreciation and amortization charges	29,19 миң	29,76 миң	29,74 миң	30,02 миң
EBITDA	-306,98 миң	-313,10 миң	-287,95 миң	-458,08 миң
Gain or loss from assets sale	-	-	-	-

Finance